Get Live Data

The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. Glaxosmithkline Share Price
  4. Glaxosmithkline Share Regulatory News
  5. Change of name to GSK plc

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,774.50
Bid: 1,774.00
Ask: 1,774.50
Change: -3.50 (-0.20%)
Spread: 0.50 (0.028%)
Open: 1,780.00
High: 1,793.50
Low: 1,766.50
Prev. Close: 1,778.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Change of name to GSK plc

16 May 2022 14:00

RNS Number : 6484L
GlaxoSmithKline PLC
16 May 2022
 

GSK plc(the 'Company')

Change of name to GSK plc

The Company today confirms its name has changed from GlaxoSmithKline plc to GSK plc.

The Company announced the decision to change its name to GSK plc on 27 April 2022 together with its first quarter 2022 results. This change has now taken effect.

The London Stock Exchange and the New York Stock Exchange will reflect the change of name in due course. 

Shareholders should note that their shareholdings will be unaffected by the change of name. Existing share certificates should be retained as they will remain valid for all purposes and no new share certificates will be issued.

The ISINs, SEDOLs, CUSIPs and ticker symbols of the Company's ordinary shares and ADS remain unchanged. The Company's Legal Entity Identifier (LEI) remains 5493000HZTVUYLO1D793.

V A WhyteCompany Secretary

16 May 2022

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CANFLFVFEVIRLIF
456789101112
Date   Source Headline
15th Mar 202210:00 amRNSAppointments to Designate Haleon Board
11th Mar 20222:55 pmRNSDirector/PDMR Shareholding
9th Mar 20221:44 pmRNSDirector/PDMR Shareholding
8th Mar 20226:24 pmRNSGSK Annual Report 2021 on Form 20-F
4th Mar 202211:03 amRNSGSK publishes Annual Report 2021
1st Mar 20222:30 pmRNSTotal Voting Rights
1st Mar 20221:18 pmRNSDirector/PDMR Shareholding
1st Mar 20229:55 amRNSDirector/PDMR Shareholding
1st Mar 20227:00 amRNSDaprodustat application accepted for review by EMA
28th Feb 202211:00 amRNSGSK introduces Haleon to investors
28th Feb 20227:00 amRNSGSK RSV maternal vaccine candidate further update
24th Feb 20224:22 pmRNSDirector/PDMR Shareholding
24th Feb 20223:12 pmRNSCanada Approval For Medicago GSK Covid-19 Vaccine
23rd Feb 20222:50 pmRNSDirector/PDMR Shareholding
22nd Feb 20222:00 pmRNSGSK Consumer Healthcare to be called Haleon
22nd Feb 20229:22 amRNSDirector/PDMR Shareholding
18th Feb 20224:30 pmRNSDirector/PDMR Shareholding
18th Feb 20227:00 amRNSGSK gives update on RSV maternal vaccine candidate
17th Feb 20224:00 pmRNSDirector/PDMR Shareholding
17th Feb 20223:40 pmRNSDirector/PDMR Shareholding
17th Feb 20223:20 pmRNSDirector/PDMR Shareholding
17th Feb 20222:50 pmRNSDirector/PDMR Shareholding
17th Feb 20222:19 pmRNSDirector/PDMR Shareholding
16th Feb 20226:04 pmRNSDirector/PDMR Shareholding
14th Feb 20225:50 pmRNSDirector/PDMR Shareholding
14th Feb 20221:26 pmRNSTransfer of Treasury Shares
11th Feb 20222:06 pmRNSDirector/PDMR Shareholding
11th Feb 20229:33 amRNSDirector/PDMR Shareholding
10th Feb 20229:00 amRNSBenlysta approved in China for Lupus Nephritis
9th Feb 202211:07 amRNSDirector/PDMR Shareholding
9th Feb 20227:00 amRNSFinal Results
7th Feb 202210:30 amRNSPublication of full year 2021 results: Replacement
7th Feb 202210:00 amRNSPublication of full year 2021 results
2nd Feb 20227:00 amRNSGSK announces settlement between ViiV and Gilead
1st Feb 20221:44 pmRNSFDA approves ViiV Healthcare’s sNDA for Cabenuva
1st Feb 202211:44 amRNSTotal Voting Rights
26th Jan 20224:48 pmRNSDirector/PDMR Shareholding
20th Jan 20223:59 pmRNSDirector/PDMR Shareholding
19th Jan 20224:33 pmRNSDirector/PDMR Shareholding
19th Jan 20223:14 pmRNSDirector/PDMR Shareholding
19th Jan 20223:10 pmRNSDirector/PDMR Shareholding
19th Jan 20227:00 amRNSTony Wood appointed CSO Designate, GSK
17th Jan 20225:04 pmRNSDirector/PDMR Shareholding
17th Jan 20223:07 pmRNSDirector/PDMR Shareholding
17th Jan 20227:00 amRNSUpdate - GSK Consumer Healthcare
14th Jan 20223:22 pmRNSDirector/PDMR Shareholding
13th Jan 20224:12 pmRNSDirector/PDMR Shareholding
11th Jan 20224:28 pmRNSDirector/PDMR Shareholding
11th Jan 202212:08 pmRNSUS Govt buys additional 600,000 sotrovimab doses
4th Jan 202212:28 pmRNSTotal Voting Rights
456789101112

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.